Skip to main content

Lunai Bioworks Inc.

corporate_fare Company Profile

Lunai Bioworks Inc.

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed LNAI - Latest Insights

LNAI
Apr 28, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
7
LNAI
Apr 28, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
7
LNAI
Apr 28, 2026, 5:00 PM EDT
Filing Type: DEFA14A
Importance Score:
7
LNAI
Apr 13, 2026, 5:15 PM EDT
Filing Type: DEF 14A
Importance Score:
8
LNAI
Apr 02, 2026, 5:01 PM EDT
Filing Type: PRE 14A
Importance Score:
8
LNAI
Mar 26, 2026, 8:52 AM EDT
Source: Reuters
Importance Score:
9
LNAI
Mar 05, 2026, 4:46 PM EST
Filing Type: 8-K
Importance Score:
9
LNAI
Feb 23, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
8
LNAI
Feb 17, 2026, 3:16 PM EST
Filing Type: 10-Q
Importance Score:
9
LNAI
Feb 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
9